CD8A and ovarian cancer: Furthermore, the improved overall survival of ID8 mice after co-treatment with compound 968 and anti-PD-L1 antibody and the higher proportion of granzyme B-expressing CD4+ and CD8+ T cells isolated from tumors from the co-treatment group provided the rationale for further experiment to confirm the efficacy and safety of this combined treatment in ovarian cancer.